Procurement Summary
Country : Japan
Summary : A Bictegravir Sodium Emtricitabine Tenofovir Alafenamide Fumarate (30Tablets/Vial) 420Vials, And 50 other Contracts
Deadline : 14 Mar 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 95553851
Document Ref. No. :
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
A Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30tablets/vial) 420vials, and 50 other contracts
Classification :
0004 Medical & Pharmaceutical Products
Summay of Notice :
⑴ Official in charge of disbursement of the procuring entity : Tatsuo Ushiki, President, National University Corporation Niigata University
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30tablets/vial) 420vials
B Letermovir (240㎎ 14tablets/case) 300 cases
C Olaparib (100㎎ 56tablets/case) 140 cases
D Olaparib (150㎎ 56tablets/case) 420 cases
E Aflibercept (Genetical Recombination) (2㎎ 0.05mL/syringe) 480syringes
F Vutrisiran Sodium Kit (25㎎ 0.5mL/syringe) 4syringes
G Tocilizumab (Genetical Recombination) (200㎎ 10mL/vial) 1, 320vials
H Tocilizumab (Genetical Recombination) (162㎎ 0.9mL/kit) 1, 080cases
I Paclitaxel (100㎎/vial) 1, 300vials
J Cetuximab (Genetical Recombination) (100㎎ 20mL/vial) 1, 350vials
K Bevacizumab (Genetical Recombination) (100㎎ 4mL/vial) 870vials
L Bevacizumab (Genetical Recombination) (400㎎ 16mL/vial) 1, 100vials
M Durvalumab (Genetical Recombination) (120㎎ 2.4mL/vial) 460vials
N Durvalumab (Genetical Recombination) (500㎎ 10mL/vial) 450vials
O Canakinumab (Genetical Recombination) (150㎎ 1mL/vial) 30vials
P Nivolumab (Genetical Recombination) (100㎎ 10mL/vial) 210vials
Q Abatacept (Genetical Recombination) (250㎎/vial) 500vials
...
Documents
Tender Notice